PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver - Pediatric
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Drug Studies
Contact Us
Log In
You need to enable JavaScript to run this app page.
Breast
HCI-031
Model Details
Patient
PDX Model
Drug Studies
Histology
Metastasis
Patient Treatment
Patient Information for Model: HCI-031
Contact Model Developer
Model Contact
Model: HCI-031
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email:
Alana.Welm@hci.utah.edu
Patient Information
Clinical Timeline
Color Keys:
Positive
Negative
N/A
Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection
Model Information for Model: HCI-031
Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Drug Studies for Model: HCI-031
Treatment Response Across All Studies
CR <=-95% to -100%
PR <-30% to >-95%
SD >=-30% to +20%
PD >=+20%
NA
Drug Study: PPRstudy
Study Metadata
Study ID:
PPRstudy
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
3
Mouse Strain:
PI:
Alana Welm
Study Title:
PPR Study
Treatments:
Birinapant, Tolinapant
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Treatment
Birinapant
10
Treatment
Tolinapant
20
Control
Vehicle
Total arms showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Birinapant
35
114
PD
Tolinapant
35
87
PD
Vehicle
35
78
PD
Total treatment results showing: 3
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Histology Information for Model: HCI-031
There are no histology images for this model.
Metastasis Information for Model: HCI-031
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar
Patient Treatment Information for Model: HCI-031
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
11
Unknown Treatment
Neoadjuvant
48.5
49.5
365 days
26
Mastectomy
Adjuvant
55.41
55.48
26 days
27
Adriamycin/Cyclophosphamide, Neulasta
Adjuvant
55.5
55.67
62 days
28
Clinical trial SWOG S0307
Adjuvant
55.68
55.83
55 days
29
Tamoxifen
Adjuvant
55.83
57.83
730 days
Progressive disease
30
Zometa
Adjuvant
55.69
57.7
734 days
Progressive disease
31
Arimidex
Adjuvant
57.85
59.85
730 days
Progressive disease
32
Exemestane, Denosumab
Adjuvant
59.91
60.0
33 days
Progressive disease
33
PALOMA-3
Adjuvant
70.0
70.5
183 days
Progressive disease
34
Paclitaxel
Adjuvant
70.75
70.83
29 days
Progressive disease
35
Xeloda
Adjuvant
70.91
71.0
33 days
Progressive disease
Please wait...
